

# Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/F626EAC3F796EN.html>

Date: February 2022

Pages: 75

Price: US\$ 2,000.00 (Single User License)

ID: F626EAC3F796EN

## Abstracts

Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 10, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Fibromyalgia (Fibromyalgia Syndrome) - Overview
- Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
- Aardvark Therapeutics Inc
- Aptinyx Inc
- Cortene Inc
- Engrail Therapeutics Inc
- Epitech Group SpA
- H. Lundbeck AS
- Imbrium Therapeutics LP
- Indaptus Therapeutics Inc
- Luye Pharma Group Ltd
- One World Cannabis Ltd
- PRISM Pharma Co Ltd
- Reven Holdings Inc
- Shanghai Lvdao Pharmaceutical Technology Co Ltd
- Statera Biopharma Inc
- Tetra Bio-Pharma Inc
- Teva Pharmaceutical Industries Ltd
- Tonix Pharmaceuticals Holding Corp
- Tryp Therapeutics Inc
- Virios Therapeutics, Inc
- Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles
- (celecoxib + famciclovir) - Drug Profile

Product Description  
Mechanism Of Action  
History of Events  
cannabidiol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CT-38 - Drug Profile  
Product Description  
Mechanism Of Action  
dronabinol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
fremanezumab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
LD-04185 - Drug Profile  
Product Description  
Mechanism Of Action  
LuAG-06466 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
LY-03012 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MS-11 - Drug Profile  
Product Description  
Mechanism Of Action  
naltrexone - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naltrexone hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action

History of Events

NP-013 - Drug Profile

Product Description

Mechanism Of Action

NYX-2925 - Drug Profile

Product Description

Mechanism Of Action

History of Events

palmidrol - Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

PPP-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

psilocybin - Drug Profile

Product Description

Mechanism Of Action

RPOT-1002a - Drug Profile

Product Description

Mechanism Of Action

Small Molecule 1 to Agonize CB1 and CB2 for Chronic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize CB1 and CB2 for Fibromyalgia and Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

History of Events

sunobinop tosylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

TNX-102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TRP-8803 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Type 1 Diabetes and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products

Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones

Featured News & Press Releases

Feb 09, 2022: Aptinyx hosts virtual portfolio review event to showcase NYX-2925 in chronic pain

Dec 03, 2021: Tryp Therapeutics to present at the H.C. Wainwright Psychedelics Conference on December 6, 2021

Dec 02, 2021: Tryp Therapeutics receives confirmation from FDA to proceed with phase 2a study in fibromyalgia

Dec 01, 2021: Virios Therapeutics achieves over 50% enrollment milestone in its phase 2b clinical trial for fibromyalgia

Nov 08, 2021: Tonix Pharmaceuticals presents positive results from phase 3 relief study of TNX-102 SL for the management of fibromyalgia at the American College of Rheumatology Convergence 2021

Sep 27, 2021: Tonix Pharmaceuticals announces oral presentation at the American College of Rheumatology Convergence 2021

Aug 16, 2021: Virios Therapeutics CEO highlights novel therapeutic approach for treating fibromyalgia and irritable bowel syndrome in Stock News now video interview

Jul 26, 2021: Virios Therapeutics highlights clinical sites fully operational in phase 2b fibromyalgia study featuring FDA "Fast Track" review designated antiviral therapy, oral IMC-1

Jun 09, 2021: Virios Therapeutics highlights safety data from phase 2a fibromyalgia trial at the International Association for the Study of Pain (IASP) World Congress



Jun 04, 2021: Virios Therapeutics announces dosing of first patient in phase 2b trial evaluating IMC-1 in patients with fibromyalgia

Jun 03, 2021: Tonix Pharmaceuticals presents positive results from phase 3 relief study of TNX-102 SL for the management of fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Jun 02, 2021: Virios Therapeutics presents phase 2a Fibromyalgia trial data on efficacy analyses of key secondary endpoints at the EULAR European Congress of Rheumatology

May 26, 2021: Tonix Pharmaceuticals announces presentation of two posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 24, 2021: Virios Therapeutics announces oral presentation of clinical data at Digestive Disease Week (DDW)

May 10, 2021: Tryp Therapeutics partners with Clinlogix for clinical trial support

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aardvark Therapeutics Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cortene Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Engrail Therapeutics Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Epitech Group SpA, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Imbrium Therapeutics LP, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Indaptus Therapeutics Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by One World Cannabis Ltd, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by PRISM Pharma Co Ltd, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Reven Holdings Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Shanghai Lvdao Pharmaceutical Technology Co Ltd, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Statera Biopharma Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tryp Therapeutics Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Virios Therapeutics, Inc, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022 (Contd..1)

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022 (Contd..2)

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

## I would like to order

Product name: Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/F626EAC3F796EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F626EAC3F796EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

